Summary
Estimating the transmission fitness of SARS-CoV-2 variants and understanding their evolutionary landscape is important for epidemiological forecasting. Existing methods are often constrained by their parametric natures and do not satisfactorily align with the observations during COVID-19. Here, we introduce a sliding-window data-driven pairwise comparison method, Differential Population Growth Rate (DPGR), that uses viral strains as internal controls to mitigate sampling biases. DPGR is applicable in time windows in which the logarithmic ratio of two variant subpopulations is approximately linear. We apply DPGR to genomic surveillance data and focus on Variants of Concern (VOCs) in multiple countries and regions. We found the log-linear assumption of DPGR can be found in appropriate time windows in many regions. We show that DPGR can provide estimates of transmission fitness and quantify the transmission advantage of key variants such as Omicron by location. We show that DPGR estimates agree with other methods for estimating pathogenic transmission. Furthermore, DPGR allowed us to construct viral fitness landscapes that capture the evolutionary trends of SARS-CoV-2, reflecting the relative changes of transmission traits for key genotypic changes represented by major variants. The straightforward log-linear regression approach of DPGR may also facilitate its easy adoption. This study shows that DPGR is a promising new tool in our repertoire for addressing future pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
HQ thanks the NSF award PIPP #2200138, BD Spoke #1761839, REU #1852042 and #2149956, Tennessee AI Initiative, internal support of the Department of Computer Science and Engineering and UTC, and internal support of School of Data Science and the Department of Computer Science at Old Dominion University. SH is partially supported by NSF REU #1852042
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
